Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 13,099 Shares of Stock

April 30, 2026 by InsiderTrades.com

Key Points

Director Barry Quart sold 13,099 shares at an average price of $50.10 (≈$656,260) under a pre‑arranged Rule 10b5‑1 plan, cutting his stake by about 51% — the transaction is disclosed in an SEC Form 4 filing.
Strong Q1 results and raised guidance: Kiniksa reported $0.27 EPS vs. $0.18 consensus and revenue of $214.3M (up ~55.5% YoY), and lifted FY‑2026 revenue guidance to $930M–$945M, driven by ARCALYST product growth.
Analysts responded positively: Multiple firms raised price targets (e.g., Jefferies to $71, Citigroup to $60), producing a consensus "Moderate Buy" and an average target around $60.86, while institutional ownership is roughly 54%.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) Director Barry Quart sold 13,099 shares of the firm's stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the sale, the director directly owned 12,546 shares of the company's stock, valued at approximately $628,554.60. The trade was a 51.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

Kiniksa Pharmaceuticals International stock opened at $52.99 on Thursday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $24.85 and a 12-month high of $54.31. The company has a market capitalization of $4.06 billion, a price-to-earnings ratio of 71.61 and a beta of 0.06. The firm's fifty day moving average price is $46.26 and its 200 day moving average price is $43.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.09. The company had revenue of $214.27 million during the quarter, compared to analysts' expectations of $207.12 million. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The firm's revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.11 EPS. Analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its holdings in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after buying an additional 532 shares during the last quarter. Osaic Holdings Inc. bought a new position in Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $31,000. Smartleaf Asset Management LLC bought a new position in Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $36,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $41,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $41,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

Positive Sentiment: Q1 results beat expectations — Kiniksa reported $0.27 EPS vs. consensus $0.18 and revenue of $214.3M (up ~55.5% YoY), driven by ARCALYST product growth. Strong beat and high-margin progress support near-term earnings confidence. Press Release
Positive Sentiment: FY‑2026 revenue guidance was raised to $930M–$945M vs. Street ~$912.7M — this upward guidance is a direct positive signal for revenue trajectory and model revisions. Guidance Release
Positive Sentiment: Product momentum: ARCALYST net product revenue reported at $214.3M in Q1 and management increased 2026 ARCALYST expectations — supports revenue durability and valuation multiple expansion. Product Revenue Release
Positive Sentiment: Pipeline catalysts: KPL‑387 Phase 2 recurrent pericarditis data expected in 2H‑2026 and a Phase 3 pivotal trial anticipated to start by year‑end — upcoming readouts could be meaningful share-price catalysts. Pipeline Release
Positive Sentiment: Analyst upgrades and price‑target raises — multiple firms lifted targets (Jefferies to $71, Citigroup to $60, Canaccord to $64, Wedbush to $59, Wells Fargo to $57), reflecting higher revenue/earnings expectations and driving buy-side interest. Analyst Coverage More Analyst Notes
Neutral Sentiment: Company materials and call: Q1 earnings slide deck and transcript are available for investors who want detail on channel dynamics, margins and guidance assumptions. Use these to validate the upbeat narrative. Earnings Presentation Call Transcript
Negative Sentiment: Insider sale: Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a pre‑arranged Rule 10b5‑1 plan, reducing his stake ~51%. While pre‑planned, insider selling can still weigh on sentiment and may contribute to near‑term price pressure. SEC Filing Insider Trade Detail

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on KNSA. Wedbush raised their price objective on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an "outperform" rating in a research note on Wednesday. Jefferies Financial Group upped their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a "buy" rating in a research report on Tuesday. Weiss Ratings reiterated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, April 21st. Citigroup raised their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Wednesday. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $60.86.

Check Out Our Latest Analysis on KNSA

About Kiniksa Pharmaceuticals International

(Get Free Report)

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.